I think some of the best ASX 200 growth shares are businesses that solve important problems for customers.
They may not always have the loudest stories on the market, but they can become more valuable by building better products, winning larger customers, and becoming harder to replace over time.
These are two ASX 200 shares I would consider buying for powerful long-term growth.
Image source: Getty Images
TechnologyOne Ltd (ASX: TNE)
TechnologyOne is one of the ASX 200's best tech shares, in my opinion.
The company provides enterprise software to councils, government departments, universities, and other large organisations. Its products help customers manage things such as finance, payroll, property and rating, student systems, and other core operations.
This is not glamorous software, and that is what I like about it.
Large organisations need systems that work. They need reliability, security, compliance, reporting, and support. Once software is built into daily operations, changing providers can be disruptive and costly.
That gives TechnologyOne a strong position with customers.
I also like the company's long-running shift to software-as-a-service. Recurring revenue can make the business more predictable, and cloud-based products can support ongoing upgrades and stronger customer relationships.
The valuation is often demanding, so investors need to be sensible about price. But I think TechnologyOne has the rare combination of a focused market, strong execution, and a long runway beyond Australia.
Pro Medicus Ltd (ASX: PME)
Pro Medicus is another ASX 200 share where highly specialised work can be the powerful part.
The company provides medical imaging software through its Visage platform. Hospitals and radiology networks need technology that can handle huge imaging files, support fast workflows, and help doctors access the information they need.
This is a serious job.
Medical imaging is central to diagnosis and treatment. As scans become more detailed and healthcare systems become more digital, software quality becomes increasingly important.
Pro Medicus has built a strong reputation in this specialist area. Its contracts can be large, long term, and strategically important to customers.
What I like is that the company is selling into a market where performance is important. Hospitals and healthcare groups are not buying software because it sounds fashionable. They need tools that improve speed, usability, and reliability in clinical settings.
The risk, again, is valuation. Pro Medicus often trades at a premium because the market already recognises its quality. But I think exceptional software businesses can keep surprising investors if they continue winning important customers and expanding their role inside large markets.
Foolish takeaway
What I like about TechnologyOne and Pro Medicus is that both companies sell software into areas where reliability, speed, and product quality really count.
That gives them a useful kind of growth profile. Their customers are not buying a passing trend, they are using systems that help run important operations, whether that is a council, a university, a hospital, or a radiology network.
If these companies keep improving their products and winning larger customers, I think they can become even more valuable over time. That is why both ASX 200 shares would be on my buy list for long-term growth.
